Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer
作者： Naiyer A. Rizvi , Gregory J. Riely , Christopher G. Azzoli , Vincent A. Miller , Kenneth K. Ng
关键词:
摘要: Purpose Nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) is an formulation of that has demonstrated improved efficacy compared with in the treatment metastatic breast cancer. We undertook this trial to determine maximum-tolerated dose (MTD) and single-agent activity NAB-paclitaxel administered on a weekly basis patients stage IV non–small-cell lung cancer (NSCLC). Patients Methods This was open-label, single-arm, phase I/II study. were treated intravenously during 30 minutes without corticosteroid or antihistamine premedications days 1, 8, 15 28-day cycle. Radiologic tumor assessment performed every 8 weeks. Results Dose levels 100 125 mg/m2 tolerated dose-limiting toxicities (DLTs). At 150 MTD exceeded; two three experienced DLT (grade 3 sensory neuropathy febrile neutropenia). The level expanded determined be MTD...
sci-hub.se 参考文章(23)
N Saijo, Y Nishiwaki, K Watanabe, I Sekine, S Yoneda, Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clinical Cancer Research. ,vol. 2, pp. 941- 945 ,(1996)
Frank V Fossella, Jin Soo Lee, Dong M Shin, Maria Calayag, Martin Huber, Roman Perez-Soler, William K Murphy, Scott Lippman, Steven Benner, Bonnie Glisson, None, Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 13, pp. 645- 651 ,(1995) , 10.1200/JCO.1995.13.3.645
H Kunitoh, K Watanabe, T Onoshi, K Furuse, H Niitani, T Taguchi, Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer : A Japanese cooperative study Journal of Clinical Oncology. ,vol. 14, pp. 1649- 1655 ,(1996) , 10.1200/JCO.1996.14.5.1649
Vincent A. Miller, James R. Rigas, Prudence A. Francis, Stefan C. Grant, Katherine M. W. Pisters, Mark G. Kris, Karen Woolley, Ennapadam S. Venkatraman, Robert T. Heelan, Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer Cancer. ,vol. 75, pp. 968- 972 ,(1995) , 10.1002/1097-0142(19950215)75:4<968::AID-CNCR2820750411>3.0.CO;2-Y
V Alberola, R Rosell, JL Gonzalez-Larriba, F Molina, F Ayala, J Garcia-Conde, D Benito, JM Perez, Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer Annals of Oncology. ,vol. 6, pp. 49- 52 ,(1995) , 10.1093/ANNONC/6.SUPPL_3.S49
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954
William J. Tester, Pamela Y. Jin, Deborah H. Reardon, Jeffrey B. Cohn, Martin H. Cohen, Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer. ,vol. 79, pp. 724- 729 ,(1997) , 10.1002/(SICI)1097-0142(19970215)79:4<724::AID-CNCR9>3.0.CO;2-D
W. K. Murphy, F. V. Fossella, R. J. Winn, D. M. Shin, H. E. Hynes, H. M. Gross, E. Davilla, J. Leimert, H. Dhingra, M. N. Raber, I. H. Krakoff, W. K. Hong, Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 85, pp. 384- 388 ,(1993) , 10.1093/JNCI/85.5.384
T Cerny, , S Kaplan, N Pavlidis, P Schöffski, R Epelbaum, J van Meerbeek, J Wanders, HR Franklin, S Kaye, Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) British Journal of Cancer. ,vol. 70, pp. 384- 387 ,(1994) , 10.1038/BJC.1994.311
C Gridelli, F Perrone, S Monfardini, Lung cancer in the elderly. European Journal of Cancer. ,vol. 33, pp. 2313- 2314 ,(1997) , 10.1016/S0959-8049(97)10050-8